ReviewNature reviews. Urology2026
20 years of taxane therapy in prostate cancer - the past, present and future.
Review in Nature reviews. Urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
2024 marked the twentieth anniversary of FDA approval for taxane therapy, namely docetaxel, in the treatment of advanced prostate cancer. Approval of this treatment modality signified a breakthrough in the field, as it demonstrated for the first time that a non-antiandrogen targeting agent could significantly improve survival of patients with prostate cancer. New evidence has further solidified the role of taxanes, demonstrating that it improves survival when used in combination with androgen-targeting therapy in early-stage metastatic hormone-sensitive prostate cancer. Consequently, taxane therapy is currently considered a gold standard and mainstay in the treatment of prostate cancer. In this Review, we present an up-to-date analysis of the pivotal role of taxanes in the treatment of prostate cancer, discuss reasons why taxanes are effective and discuss how the mechanisms that confer resistance to taxanes in prostate cancer might be exploited to develop more effective therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.